Received Jul 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 95DB2 | — |
couple of patients receiving expired vaccines and they were approximately 1 month expired; This non-serious case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in an unspecified number of patients who received HAV (Havrix) (batch number 95DB2, expiry date 13-DEC-2024) for prophylaxis. In JAN-2025, the patient received Havrix. In JAN-2025, an unknown time after receiving Havrix, the patient experienced expired vaccine used (Verbatim: couple of patients receiving expired vaccines and they were approximately 1 month expired). The outcome of the expired vaccine used was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 03-APR-2025 The reporter had a couple of patients who received an expired Havrix vaccines, and they were approximately 1 month expired. The reporter was calling to verify if GlaxoSmithKline have any data on effectiveness of their vaccines after the expiration, to see if they need to revaccinate these patients or if what was given was considered effective by some of GSKs post data. The vaccines were administered January 16th till January 30th, 2025. The vaccine administration facility was the same as primary reporter. No other information was provided.